Provider delay in treatment initiation and its influence on survival outcomes in women with operable breast cancer.

Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
Christian H Flores-BalcázarJuan E Bargalló-Rocha

Abstract

The goal of this study was to determine whether a delay in starting treatment via surgery or neoadjuvant chemotherapy is related to a decrease in cancer-specific survival (CSS) in women with operable breast cancer (BrCr). Limited medical infrastructure and a lack of cancer prevention awareness in low- and middle-income countries have caused high BrCr incidence and mortality rates. We analyzed a retrospective cohort of 720 women treated at a single center from 2005 to 2012. CSS estimates were obtained by the Kaplan-Meier method. A Cox model of proportional risks was performed to obtain the risk of dying from BrCr. We also obtained the risk according to the category of treatment initiation. Women with locally advanced stages and without hormone receptor expression were more likely to initiate treatment after 45 days. Patients in Stage IIIA had a 78.1% survival if treatment was initiated before 45 days (95% CI, 0.70-0.84) and 63.6% survival if treatment was started after 45 days (95% CI, 0.44-0.78; p < 0.001). Patients in Stage IIIB had a 62.9% survival if treatment was initiated before 45 days (95% CI, 0.53-0.72) and 57.4% survival if treatment started after 45 days (95% CI, 0.31-0.89; p < 0.001). Prognostic factors in which lowe...Continue Reading

References

Jan 13, 2004·The British Journal of Surgery·M D BarberJ M Dixon
Oct 7, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Emily Rose SmithJames R Hebert
Oct 9, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Maximino RedondoEugenio Jimenez
Jan 9, 2010·Salud pública de México·Karla Unger-Saldaña, Claudia Infante-Castañeda
Mar 5, 2011·The Breast : Official Journal of the European Society of Mastology·Kristin BrightSilvia C Formenti
May 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y H YunD S Heo
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John M McLaughlinElectra D Paskett
Nov 28, 2013·The Oncologist·Cynthia Villarreal-GarzaCarlos Barrios
Aug 13, 2014·World Journal of Clinical Oncology·Karla Unger-Saldaña
Mar 27, 2015·Cancer·Karla Unger-SaldañaJesús Miguel Lázaro-León
Apr 11, 2015·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Meritxell ArenasJordi Colomer
Sep 24, 2016·Medicine·Mostafa DianatinasabMohammad Zare-Bandamiri
Feb 23, 2019·Ecancermedicalscience·Cynthia Villarreal-GarzaKarla Unger-Saldaña
Oct 3, 2019·CA: a Cancer Journal for Clinicians·Carol E DeSantisRebecca L Siegel

❮ Previous
Next ❯

Citations

Sep 12, 2020·World Journal of Clinical Cases·Jaime González-MonteroLuis Villanueva
Jul 20, 2021·Journal of the American College of Radiology : JACR·Jasmine M Miller-KleinhenzLauren E McCullough

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Tae-Kyung YooDong-Young Noh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John M McLaughlinElectra D Paskett
© 2021 Meta ULC. All rights reserved